Cancer-associated VTE (CAT)


Cancer increases VTE risk (Illustration: MostPhotos.com) 
Cancer is associated with a substantial risk of VTE, and cancer-associated thrombosis (CAT) is associated with more severe complications such as prolonged hospital stay, increased bleeding risk, VTE recurrence and high mortality rate.

In this project, we use data from the Tromsø study, the Trøndelag Health Study (HUNT) and the Scandinavia Thrombosis and Cancer (STAC) cohort, which is a merged cohort of Tromsø, HUNT and the Diet Cancer and Health Study (DCH, Denmark). We investigate the epidemiology and risk factors of occult and over cancer-associated VTE, as well as interactions of cancer and genetic risk factors on VTE risk. 

Principal Investigator: John-Bjarne Hansen

External collaborators: Nick van Es (Amsterdam University Medical Center), Søren Risom Kristensen, Inger Lise Gade (Aalborg University, Denmark)Kristian Hveem (HUNT Center for Clinical and Molecular Epidemiology), Frits Rosendaal and Suzanne Cannegieter (Leiden University Medical Center)

Publications: 

Crobach et al. Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study. Blood Adv. 2023; 7: 4072-9.

Skille et al. Prothrombotic genotypes and risk of venous thromboembolism in occult cancer. Thromb Res. 2021; 205: 17-23.

Paulsen et al. Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort. Sci Rep. 2021; 11: 18752.

Skille et al. Genetic variation of platelet glycoprotein VI and the risk of venous thromboembolism. Haematologica. 2020; 105: e358-e60.

Skille et al. Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event. J Thromb Haemost. 2020; 18: 2861-9.

Paulsen et al. Fibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolism. Haematologica. 2020; 105: 1963-8.

Gran et al. Prothrombotic genotypes and risk of venous thromboembolism in cancer. Thromb Res. 2018; 164 Suppl 1: S12-S8.

Gade et al. Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open. 2018; 2: e131-e8.

Gran et al. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2017; 15: 1361-7.

Gran et al. D-dimer measured at first venous thromboembolism is associated with future risk of cancer. Haematologica. 2016; 101: e473-e5.

Gade et al. Epidemiology of venous thromboembolism in hematological cancers: The Scandinavian Thrombosis and Cancer (STAC) cohort. Thromb Res. 2017; 158: 157-60.

Gran et al. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. Haematologica. 2016; 101: 1046-53.

Blix et al. Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort. J Thromb Haemost. 2018; 16: 1327-35.

Gade et al. The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. J Thromb Haemost. 2017; 15: 1567-75.

Jensvoll et al. Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clin Epidemiol. 2015; 7: 401-10.

Jensvoll et al. Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromso Study. PloS one. 2014; 9: e92011.

Blix et al. The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromso study. Eur J Epidemiol. 2014; 29: 277-84

Blix et al. White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromso study. PloS one. 2013; 8: e73447.



Members:

John Bjarne Hansen (Principal investigator)
Vania Maris Morelli
Sigrid Kufaas Brækkan
Nikolai Hagensen Eide
Camilla Langholm


Financial/grant information:

North Norwegian Regional Health Authority (Helse Nord)

Wilhelmsen Foundation

Stiftelsen K.G. Jebsen